Монокалий-фосфат

136.09

135.932770

231-913-4

4J9FJ0HL51

1608

DTXSID0035667

Colorless crystals or white granular powder|White tetragonal crystals

28352400

80.6

-0.49040

White transparent powder

2.34 g/cm³

253 °C

158ºC at 760 mmHg

Index of refraction: 1.5093, 1.4682, both at 589 nm

H2O: 222 g/L (20 ºC)

Store at RT.

LD50 skin in rabbit: > 4640mg/kg

Odorless

Between 4,2 and 4,8 (1 % solution)

Permanent in air. At 400 °C loses water, forming metaphosphate|pH = 4.5 (1% aqueous solution). Forms ferroelectric crystals (Critical temperature = -151 °C)|At ordinary temperatures, monopotassium phosphate is so far above its Curie point as to give piezoelectric effects in which the emf is proportional to the distorting force. There is virtually no hysteresis.|Curie point: 123 K; Spontaneous polarization: 4.7 uC/cu cm at 110 K

Critical temperature = -151 °C

3260

2

36/38-35-22

24/25-45-36/37/39-26

TC6615500

F,T,C,Xi,Xn

Separated from strong bases.

Stable under normal temperatures and pressures.

P260, P261, P264, P270, P271, P280, P301+P312, P301+P330+P331, P302+P352, P303+P361+P353, P304+P340, P305+P351+P338, P310, P312, P321, P330, P332+P313, P337+P313, P362, P363, P403+P233, P405, P501

H302

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal and plant life; and conformance with environmental and public health regulations.

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl potassium phosphate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.|Potassium phosphates (mono, di, and tribasic) are indirect food additives for use only as components of adhesives.

WHO; Diseases Caused by Phosphorus and Its Toxic Compounds; Early Detection of Occupational Diseases pg 53-62 (1986). Review of diseases and health related effects resulting from exposure to phosphorus or phosphorus cmpd.

Not combustible. Gives off irritating or toxic fumes (or gases) in a fire.

Not Classified

Engineering controls such as exhaust ventilation are recommended.|When working with small quantities in a well-ventilated area, respiratory protection may not be required. The use of an approved dust mask is recommended.

Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials.|As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.

Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labeled container for disposal. Wash spill site.

As a general rule, when handling USP Reference standards avoid all contact and inhalation of dust, mist and or vapors associated with the material. Wash thoroughly after handling.|This material is assumed to be combustible. As with all dry powders it is advisable to ground mechanical equipment in contact with dry material to dissipate the potential build up of static electricity.|/Wear/ chemically compatible gloves, safety glasses or goggles and protect exposed skin.

Personal protection: particulate filter respirator adapted to the airborne concentration of the substance. Sweep spilled substance into covered containers.

Separated from strong bases.

A harmful concentration of airborne particles can be reached quickly when dispersed, especially if powdered.

The substance is irritating to the eyes, skin and respiratory tract.

Use ventilation (not if powder), local exhaust or breathing protection.

Protective gloves.

Wear safety goggles.

Rabbit : LD50 >4640mg/kg (skin) Rat : LdLo : 4640mg/kg (Oral)

Potassium supplements should not be administered to patients receiving potassium-sparing drugs such as amiloride, spironolactone, and triamterene. /Potassium Supplements/|Concurrent use with potassium and sodium phosphates combination or monobasic potassium phosphate may increase plasma concentrations of salicylates since salicylate excretion is decreased in acidified urine; addition of these phosphates to patients stabilized on a salicylate may lead to toxic salicylate concentrations.|Concurrent use with foods or medicines containing phosphates will decrease iron absorption because of the formation of less soluble or insoluble complexes; iron supplements should not be taken within 1 hour before or 2 hours after ingestion of phosphates. /Phosphates/|Use of potassium phosphates injection in digitalized patients with severe or complete heart block is not recommended because of possible hyperkalemia. /Phosphates/|For more Interactions (Complete) data for MONOPOTASSIUM DIHYDROGEN PHOSPHATE (8 total), please visit the HSDB record page.

LD50 Mouse oral 2820 mg/kg bw|LD50 Rat oral 3200 mg/kg bw|LD50 Mouse oral about 1700 mg/kg bw

Potassium supplements are contraindicated in patients with severe renal impairment with oliguria, anuria, or azotemia; untreated chronic adrenocortical insufficiency (Addison';s disease); the hyperkalemic form of familial periodic paralysis or other hyperkalemias; acute dehydration; heat cramps; or extensive tissue breakdown such as severe burns. /Potassium Supplements/

In healthy adults, plasma potassium concentrations generally range from 3.5-5 mEq/L. Plasma concentrations up to 7.7 mEq/L may be normal in neonates.

Monopotassium dihydrogenphosphate sorption was measured on soil and peat with the following results: 440 ug/g (Sceptre soil; 4.5% organic matter; 49% clay); 440 ug/g Melfort soil; 10% organic matter; 46% clay); 375 ug/g (Saskatchewan peat; characteristics not specified)(1).

According to the 2006 TSCA Inventory Update Reporting data, the number of persons reasonably likely to be exposed in the industrial manufacturing, processing, and use of monopotassium dihydrogen phosphate is 1000 or greater; the data may be greatly underestimated(1).

Used in buffers (determination of pH, pharmaceutical production, urinary acidifier, paper processing, baking powder, and food), nutrient solutions, yeast foods, special liquid fertilizers, sonar systems and other electronic applications; Used as a nutritional supplement in foods, a nonlinear optical material for laser use, and in wastewater treatment;

The solution is intended to provide phosphate ion, (PO4-3) for addition to large volume infusion fluids for intravenous use. Potassium Phosphates Injection, USP, 3 mM P/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of potassium (4.4 mEq/mL) must be calculated into total electrolyte content of such prepared solutions.|Urinary acidification by potassium and sodium phosphates combination and monobasic potassium phosphate